Osaka, Japan

Tatsuo Shimizu

USPTO Granted Patents = 4 

 

Average Co-Inventor Count = 5.1

ph-index = 2

Forward Citations = 17(Granted Patents)


Company Filing History:


Years Active: 2001-2016

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Innovations of Tatsuo Shimizu in Antibody Development

Introduction

Tatsuo Shimizu is a prominent inventor based in Osaka, Japan, known for his significant contributions to the field of biotechnology. He holds a total of four patents, focusing primarily on therapeutic agents for tissue fibrosis and cancer. His work has paved the way for advancements in medical treatments, particularly through the development of specific antibodies.

Latest Patents

Shimizu's latest patents include the creation of an anti-human CCR7 antibody, which is designed to serve as a therapeutic agent for tissue fibrosis or cancer. This innovative antibody specifically binds to an extracellular domain of human CCR7 and includes a heavy chain CDR3 with specific amino acid sequences. The invention also encompasses a pharmaceutical composition that utilizes this anti-human CCR7 antibody, which may interfere with CCR7-dependent intracellular signal transduction mechanisms. The detailed specifications of the antibody highlight its potential as a crucial component in cancer treatment.

Career Highlights

Throughout his career, Tatsuo Shimizu has worked with notable companies such as Sekisui Chemical Co., Ltd. and Sekisui Kagaku Kogyo Kabushiki Kaisha. His experience in these organizations has contributed to his expertise in the development of innovative biopharmaceuticals. Shimizu's work has been instrumental in advancing therapeutic options for patients suffering from serious medical conditions.

Collaborations

Shimizu has collaborated with esteemed colleagues, including Tomoko Horiguchi and Kiyoshi Kuriyama. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas in the field of biotechnology.

Conclusion

Tatsuo Shimizu's contributions to the development of anti-human CCR7 antibodies represent a significant advancement in the treatment of tissue fibrosis and cancer. His innovative work continues to inspire future research and development in the field of biotechnology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…